Soleno Therapeutics Faces Securities Fraud Lawsuit Over Undisclosed Safety Issues

Kahn Swick & Foti, LLC has announced a class action securities lawsuit against Soleno Therapeutics, Inc., alleging the company failed to disclose material safety concerns regarding its only commercial product during a critical nine-month period in 2025. The lawsuit centers on alleged securities fraud and covers the period between March 26, 2025 and November 4, 2025, with investors having until May 5, 2026 to file applications as lead plaintiffs in the case.

The claims represent a significant threat to Soleno Therapeutics, a specialized biopharmaceutical company focused on treating rare genetic disorders. The litigation underscores the high stakes and regulatory scrutiny surrounding pharmaceutical companies' disclosure obligations, particularly for companies with limited product portfolios where a single drug represents the bulk of revenue.

The Allegations and Product at Issue

At the center of the lawsuit is DCCR, Soleno Therapeutics' only commercial product, which is indicated for treating hyperphagia—excessive hunger and food consumption—in patients with Prader-Willi syndrome (PWS). According to the legal complaint, the company allegedly failed to disclose material safety concerns that emerged during the class period, most notably evidence of excessive fluid retention in patients using the drug.

The allegations carry particular weight given the specific nature of the claims:

• Primary concern: Evidence of excessive fluid retention associated with DCCR use
• Timing: Safety issues allegedly emerged or became known during the March 26 - November 4, 2025 window
• Significance: DCCR represents the company's sole commercial revenue source
• Patient population: Treatment for a rare genetic disorder affecting metabolism and appetite regulation

The failure to disclose such material safety information violates federal securities laws, which require public companies to promptly and accurately disclose risks that could materially affect investor decisions. The timing of the alleged non-disclosure is particularly significant, as it suggests the company may have been aware of safety data that would likely have triggered stock price adjustments had it been properly disclosed.

Market Context: Rare Disease Biotech Under Heightened Scrutiny

The lawsuit arrives amid intensifying regulatory and investor scrutiny of biopharmaceutical companies with narrow product portfolios. Unlike larger pharma firms with diversified drug pipelines, single-product companies face heightened vulnerability to safety concerns or efficacy questions, as one adverse event can threaten the entire business model.

Soleno Therapeutics operates in the competitive but lucrative rare disease market, where companies can command premium pricing for treatments addressing unmet medical needs. However, this advantage comes with corresponding responsibility for transparent safety reporting. The Prader-Willi syndrome treatment space represents a niche opportunity, but companies in this sector must navigate complex regulatory relationships with the FDA and maintain stringent disclosure practices.

The broader context includes:

• Regulatory environment: Enhanced FDA scrutiny of post-market safety data, particularly for rare disease treatments
• Disclosure standards: Securities regulations requiring prompt disclosure of material adverse safety information
• Investor expectations: Heightened vigilance from institutional investors regarding pharmaceutical safety disclosure
• Precedent: Multiple prior settlements involving pharmaceutical companies' failure to disclose safety issues

Investor Implications and Legal Process

For shareholders who purchased Soleno Therapeutics stock during the class period, the lawsuit represents a potential avenue for recovery. The lead plaintiff process, with a deadline of May 5, 2026, allows investors to petition the court to serve as representative plaintiffs in the case. Lead plaintiffs are typically selected based on the size of their investment losses and their ability to fairly represent the broader class.

The financial implications for Soleno Therapeutics could be substantial, depending on the lawsuit's outcome. Potential consequences include:

• Damages liability: Settlements in pharmaceutical securities fraud cases typically range from millions to hundreds of millions of dollars
• Operational disruption: Management and legal resources diverted to litigation defense
• Reputation damage: Reduced investor confidence and potential impacts on partnerships or licensing agreements
• Stock impact: Continued pressure on share price if safety concerns are validated
• Regulatory scrutiny: Potential enhanced FDA oversight of DCCR and future product applications

Investors seeking more information or considering lead plaintiff status are directed to contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, the law firm representing the class.

Forward-Looking Considerations

The unfolding litigation will likely determine whether Soleno Therapeutics management acted appropriately in its disclosure practices or whether the company deliberately or negligently withheld material safety information from investors. The resolution of this case will have implications extending beyond the company itself, potentially influencing how other rare disease biotech firms approach safety reporting and investor communication.

The May 5, 2026 deadline for lead plaintiff applications marks an important milestone, after which the litigation will likely move toward discovery and potential settlement negotiations. For Soleno Therapeutics shareholders and prospective investors, the outcome of this case represents a critical test of the company's governance, integrity, and long-term viability in an increasingly competitive and scrutinized pharmaceutical landscape.